Publications
5491 Results
- Journal / Conference
- J Clin Oncol 39, 2021 (suppl 6; abstr 428) (ASCO GU Cancers Symposium (Feb 13-15, 2021 virtual), poster)
- Year
- 2021
- Research Committee(s)
- Genitourinary
- Study Number(s)
- S1806
INTACT (S/N1806): Phase III Randomized Trial of Concurrent Chemoradiotherapy with or without Atezolizumab in Localized Muscle Invasive Bladder Cancer. Toxicity update on first 73 patients
- Journal / Conference
- J Clin Oncol 39, 2021 (suppl 15; abstr 4541) (American Society of Clinical Oncology Annual Meeting 2021, poster session)
- Year
- 2021
- Research Committee(s)
- Genitourinary
- Study Number(s)
- S1605
Phase II Trial of Atezolizumab in BCG-Unresponsive Non-Muscle Invasive Bladder Cancer: SWOG S1605 (NCT #02844816)
- Journal / Conference
- J Clin Oncol 39, 2021 (suppl 15; abstr 4131) (American Society of Clinical Oncology Annual Meeting 2021, poster session)
- Year
- 2021
- Research Committee(s)
- Gastrointestinal
- Study Number(s)
- S1505
Body Composition Measurements and Overall Survival in Patients with Resectable Pancreatic Adenocarcinoma (SWOG Study S1505)
- Journal / Conference
- J Clin Oncol 39, 2021 (suppl 15; abstr 4104) (American Society of Clinical Oncology Annual Meeting 2021, poster session)
- Year
- 2021
- Research Committee(s)
- Gastrointestinal
- Study Number(s)
- S0809
Does Adjuvant Chemoradiation Benefit Patients with Lymph Node Positive Biliary Tract Cancers? : A Secondary Analysis of SWOG S0809
- Journal / Conference
- J Clin Oncol 39, 2021 (suppl 15; abstr 9075) (American Society of Clinical Oncology Annual Meeting 2021, poster session)
- Year
- 2021
- Research Committee(s)
- Lung
- Study Number(s)
- S1800A
Phase II randomized study of ramucirumab plus pembrolizumab versus standard of care for advanced non-small cell lung cancer—toxicity update (Lung-MAP non-matched sub-study S1800A)
- Journal / Conference
- J Clin Oncol 39, 2021 (suppl 15; abstr TPS7567) (American Society of Clinical Oncology Annual Meeting 2021 (TIPS), poster session)
- Year
- 2021
- Research Committee(s)
- Leukemia
- Study Number(s)
- S1925
Randomized, Phase III Study of Early Intervention with Venetoclax and Obinutuzumab versus Delayed Therapy with Venetoclax and Obinutuzumab in Newly Diagnosed Asymptomatic High-Risk Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (Cll/Sll): Evolve Cll/Sll Study (SWOG S1925; NCT#04269902)
- Journal / Conference
- J Clin Oncol 39, 2021 (suppl 15; abstr 9024) (American Society of Clinical Oncology Annual Meeting 2021, poster discussion session)
- Year
- 2021
- Research Committee(s)
- Lung
- Study Number(s)
- S1900A
A Phase II Study of Rucaparib in Patients with Genomic LOH High and/or Deleterious BRCA 1/2 Mutation Stage IV Non-Small Cell Lung Cancer (Lung-Map Sub-Study): SWOG S1900A
- Journal / Conference
- J Clin Oncol 39, 2021 (suppl 15; abstr 5001) (American Society of Clinical Oncology Annual Meeting 2021, oral)
- Year
- 2021
- Research Committee(s)
- Genitourinary
- Study Number(s)
- S1216
SWOG S1216: A phase III randomized trial comparing androgen deprivation therapy (ADT) plus TAK-700 with ADT plus bicalutamide in patients (pts) with newly diagnosed metastatic hormone-sensitive prostate cancer (mHSPC) (NCT01809691)
- Journal / Conference
- J Clin Oncol 39, 2021 (suppl 15; abstr 9501) (American Society of Clinical Oncology Annual Meeting 2021, oral)
- Year
- 2021
- Research Committee(s)
- Melanoma
- Study Number(s)
- S1404
Final Analysis of Overall Survival (OS) and Relapse-Free-Survival (RFS) in the Intergroup S1404 Phase III Randomized Trial Comparing Either High Dose Interferon (HDI) or Ipilimumab to Pembrolizumab in Patients with High Risk Resected Melanoma
- Journal / Conference
- J Clin Oncol 39, 2021 (suppl 15; abstr 7503) (American Society of Clinical Oncology Annual Meeting 2021, oral)
- Year
- 2021
- Research Committee(s)
- Lymphoma
- Study Number(s)
- CTSU/E1411